Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Inversago Pharma Inc.
Headquarters: Montreal, QC, Canada
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jan 8, 2025
Management Tracks
New CMOs for Alltrna, Kura, Aro
Plus: Monahan becomes chief commercial officer of Amylyx and more
BioCentury | Sep 20, 2024
Product Development
Novo’s Phase II miss in obesity oral amps up pressure on BD
Ph II data from CB1 blocker monlunabant show poor weight loss at 16 weeks, plus neuropsychiatric adverse events
BioCentury | Jan 23, 2024
Data Byte
Centerview advised most of the sellers in 2023’s largest M&A deals
Centerview Partners acted as an adviser to 64% of the biotechs acquired in $1B+ deals
BioCentury | Nov 10, 2023
Data Byte
AstraZeneca-Eccogene among largest obesity deals year-to-date
AZ tries again in GLP-1 space, as Lilly and Novo deals this year show push into new mechanisms
BioCentury | Aug 30, 2023
Regulation
Aug. 30 Quick Takes: With Embark acquisition, Novo gains another obesity asset
Plus: Epigenome editing company Epigenic raises $32M series A and updates from Outlook, InflaRx, Zealand and FDA
BioCentury | Aug 22, 2023
Deals
Why 5AM and Versant forged a deal to unite two cannabinoid companies
With interest in CB1 on the rise, the longtime backers of Bird Rock saw a path forward by joining its asset with Skye’s
BioCentury | Aug 11, 2023
Deals
Novo’s Inversago takeout brings another appetite and glucose modulator to its obesity arsenal
Inversago’s program was geared to revive CB1 receptor as a metabolic target by avoiding the central nervous system
BioCentury | Aug 10, 2023
Product Development
Obesity mechanisms in the clinic: which overlap, and which branch out
Like incretins, most clinical programs modulate glucose homeostasis and appetite, but a few work in new ways that could be more selective for fat loss
BioCentury | Oct 20, 2022
Deals
Oct. 19 Quick Takes: ‘Dark genome’ autoimmunity play Nucleome raises £37.5M series A
Plus venture rounds for Orionis, PIC, Inversago; PTC slips after pausing Huntington trial and more
Items per page:
1 - 10 of 13